Oseltamivir is appropriate for the treatment of acute, uncomplicated influenza A or B illness in adults and pediatric patients, including neonates greater than 2 weeks of age. Neonates less than 2 weeks of age may also receive oseltamivir for treatment of influenza, but safety and efficacy in this population have not been established. Multiple national advisory bodies have endorsed the use of oseltamivir as soon as possible (ideally less than 48 hours after symptom onset) for patients hospitalized with influenza or with significant comorbidities making them at high risk for complications. There is some evidence in hospitalized patients that oseltamivir can have efficacy up to 4 to 5 days after symptoms onset and hence, recommendations endorse ordering oseltamivir for hospitalized patients with severe or progressive influenza illness or those patients at high risk of developing complications, regardless of the time of symptom onset. Individuals at high risk for complications include young children (less than two years of age), those in nursing homes, those 65 years of age or older, obese, pregnant, patients with pulmonary, liver, renal, or cardiovascular disease, malignancy, neurodevelopmental disorders, metabolic disorders, epilepsy, muscular dystrophy, and immunosuppression. Empiric treatment with oseltamivir can shorten the duration of illness and is thus recommended for healthy individuals with symptoms suggestive of influenza, even before confirmation testing if treatment can commence within 48 hours of symptoms. Oseltamivir is also useful for influenza prophylaxis within 48 hours of contact with an infected individual in adults and children greater than 1 year of age.
Recommendations endorsing oseltamivir as the drug of choice for treatment and prophylaxis of illness caused by avian influenza strains, including the highly pathogenic avian influenza A (H5N1), come from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).
Oseltamivir is an antiviral neuraminidase inhibitor, with potent and selective competitive inhibition of the influenza virus neuraminidase, an enzyme necessary for viral replication. Oseltamivir phosphate is an inactive prodrug that exerts pharmacologic activity when hydrolyzed in vivo to the active form, oseltamivir carboxylate. This activated form interferes with the release of progeny influenza virus from infected host cells and thus halts the spread of infection to new host cells. Oseltamivir reduces the duration of shedding and the viral titer and can shorten the length of symptoms by 0.5 to 3 days.
Dosing of oseltamivir phosphate is via the oral route, and it is not necessary to time administration with meals. It is available in capsule form of three different dosages (30, 45, and 75 mg) and as an oral powder for reconstitution to suspension for pediatric patients. Therapy should initiate as early as possible, and maximum benefit is derived when initiated within 48 hours of onset of illness. However, in severe illness or patients at risk of complications, treatment must be initiated even beyond the 48-hour window.
Seasonal Influenza A and B treatment (five-day oral course):
Patients with severe infections admitted to an intensive care unit or who are immunosuppressed may require oseltamivir treatment for a prolonged indeterminate duration (more than 5 days).
Treatment dosing adjustments for creatinine clearance:
Seasonal Influenza A and B Prophylaxis (seven to 10-day oral course):
While recommendations for oseltamivir include the treatment of avian influenza infections, the optimum dosage and duration of treatment are unknown for these infections.
Oseltamivir is generally well tolerated. Most common side effects are nausea (up to 10%), vomiting (2% to 15%), abdominal pain, diarrhea, headache, insomnia, and vertigo. Other side effects occurring less than 1% of the time include conjunctivitis, epistaxis, allergy, arrhythmia, GI bleeding, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, confusion, hepatitis, seizures, and neuropsychiatric events. Vomiting is the most frequently reported side effect in children (16% of children aged 1 to 12 years).
Known allergies or hypersensitivities to oseltamivir or any component of the drug is a contraindication. It is pregnancy class C. Commercially available oral suspension of oseltamivir contains sorbitol and hence, should be used cautiously in patients with hereditary fructose intolerance. Oseltamivir should not be used in patients with influenza illnesses that are due to strains confirmed as resistant to oseltamivir. It should not be used for diseases that are caused by organisms other than influenza viruses.
Neuropsychiatric events such as self-injury, confusion, and delirium should be monitored, especially in children; this has mainly been reported in children in Japan and has also has correlations with fatalities.
Oseltamivir is generally very well tolerated and has few if any, drug interactions. Multiple animal toxicity studies, both pre and post-marketing of oseltamivir, have indicated respiratory suppression, as a result of central nervous system suppression, hypothermia, hypoactivity, and sudden death. This adverse event correlates with sudden-onset type neuropsychiatric reactions in human patients (especially children from Japan), but no definitive link has been established.
Oseltamivir is used widely across the world for the treatment and prophylaxis of influenza illness, both confirmed and suspected cases. (Level I) However, many practitioners are not aware of the correct indications and uses of oseltamivir as guided by existing scientific evidence. There is a lack of knowledge of the use of oseltamivir in severe or complicated influenza illness, and confusion exists about whether oseltamivir is curative for influenza. (Level I)
When suspicion of influenza illness exists during the viral season in any adult or pediatric patient with chronic conditions or severe illness requiring hospitalization, the treating physician must initiate oseltamivir treatment immediately, regardless of the duration of symptoms. (Level I) The physician needs to make sure that proper specimens are sent to the laboratory promptly for testing, and the pathologists are responsible for rapid testing and confirmatory results, including susceptibility testing to ensure optimal duration of therapy. While the efficacy of oseltamivir in immunocompromised patients is not established, the treating physician must consult with specialists regarding the use of oseltamivir in influenza illness in immunocompromised patients. (Level III)
In both pediatric and geriatric patients, as well as neurodevelopmentally challenged patients, the treating physician must partner with the nursing staff and the family members to find the right preparation of oseltamivir that will be tolerated by the patient without side effects. A pharmacist must also be engaged to dispense the proper preparation of the oral suspension.
|||Cooper NJ,Sutton AJ,Abrams KR,Wailoo A,Turner D,Nicholson KG, Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed.). 2003 Jun 7; [PubMed PMID: 12791735]|
|||Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018. Pediatrics. 2017 Oct; [PubMed PMID: 28870977]|
|||Fiore AE,Fry A,Shay D,Gubareva L,Bresee JS,Uyeki TM, Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2011 Jan 21; [PubMed PMID: 21248682]|
|||Harper SA,Bradley JS,Englund JA,File TM,Gravenstein S,Hayden FG,McGeer AJ,Neuzil KM,Pavia AT,Tapper ML,Uyeki TM,Zimmerman RK, Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Apr 15; [PubMed PMID: 19281331]|
|||Treanor JJ,Hayden FG,Vrooman PS,Barbarash R,Bettis R,Riff D,Singh S,Kinnersley N,Ward P,Mills RG, Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 Feb 23; [PubMed PMID: 10697061]|
|||Welliver R,Monto AS,Carewicz O,Schatteman E,Hassman M,Hedrick J,Jackson HC,Huson L,Ward P,Oxford JS, Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001 Feb 14; [PubMed PMID: 11176912]|
|||Beigel JH,Farrar J,Han AM,Hayden FG,Hyer R,de Jong MD,Lochindarat S,Nguyen TK,Nguyen TH,Tran TH,Nicoll A,Touch S,Yuen KY, Avian influenza A (H5N1) infection in humans. The New England journal of medicine. 2005 Sep 29; [PubMed PMID: 16192482]|
|||Hayden FG,Atmar RL,Schilling M,Johnson C,Poretz D,Paar D,Huson L,Ward P,Mills RG, Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. The New England journal of medicine. 1999 Oct 28; [PubMed PMID: 10536125]|
|||Peters PH Jr,Gravenstein S,Norwood P,De Bock V,Van Couter A,Gibbens M,von Planta TA,Ward P, Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. Journal of the American Geriatrics Society. 2001 Aug; [PubMed PMID: 11555062]|
|||Ueda N,Umetsu R,Abe J,Kato Y,Nakayama Y,Kato Z,Kinosada Y,Nakamura M, Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biological [PubMed PMID: 26424023]|
|||Toovey S,Prinssen EP,Rayner CR,Thakrar BT,Dutkowski R,Koerner A,Chu T,Sirzen-Zelenskaya A,Britschgi M,Bansod S,Donner B, Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Advances in therapy. 2012 Oct; [PubMed PMID: 23054689]|
|||Nicholson KG,Aoki FY,Osterhaus AD,Trottier S,Carewicz O,Mercier CH,Rode A,Kinnersley N,Ward P, Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (London, England). 2000 May 27; [PubMed PMID: 10866439]|
|||Chik KW,Li CK,Chan PK,Shing MM,Lee V,Tam JS,Yuen PM, Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong medical journal = Xianggang yi xue za zhi. 2004 Apr; [PubMed PMID: 15075430]|